| Serial Number | 79169309 |
| Word Mark | ADLIB |
| Filing Date | Tuesday, April 28, 2015 |
| Status | 707 - PARTIAL SECTION 71 ACCEPTED |
| Status Date | Saturday, June 10, 2023 |
| Registration Number | 5139363 |
| Registration Date | Tuesday, February 14, 2017 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 29, 2016 |
| Certificate of Correction for Registration | In the statement, "the entire class 042" should be deleted, and Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals should be inserted. |
| Goods and Services | [ Monoclonal antibodies for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ] |
| Goods and Services | [ Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; design and development of medical technology; research and development in the field of biotechnology; pharmaceutical research and development; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ] * Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; ] research and development in the field of biotechnology; pharmaceutical research and development; [ conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; ] technical project studies in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical [ or veterinary ] purposes and pharmaceutical products; research and development of new products for others [ ; design and development of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; providing temporary use of non-downloadable business software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; rental of computer software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals; cloud computing featuring software for use in research and development of monoclonal antibodies for medical or veterinary purposes and monoclonal antibody-based biopharmaceuticals * ] |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | G - NOT AVAILABLE |
| Class Status Date | Saturday, June 10, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, July 25, 2015 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Chiome Bioscience Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | Tokyo 151-0071 JP |
| Party Name | Chiome Bioscience Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Tokyo 151-0071 JP |
| Party Name | Chiome Bioscience Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Tokyo 151-0071 JP |
| Event Date | Event Description |
| Monday, April 1, 2024 | PARTIAL INVALIDATION PROCESSED BY THE IB |
| Monday, February 26, 2024 | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB |
| Monday, February 26, 2024 | INVALIDATION PROCESSED |
| Saturday, February 10, 2024 | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Saturday, June 10, 2023 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED |
| Saturday, June 10, 2023 | REGISTERED - PARTIAL SEC 71 ACCEPTED |
| Monday, May 29, 2023 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Tuesday, November 15, 2022 | TEAS SECTION 71 RECEIVED |
| Monday, February 14, 2022 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Wednesday, March 7, 2018 | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE |
| Friday, February 23, 2018 | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Saturday, October 28, 2017 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Friday, September 15, 2017 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, September 15, 2017 | FINAL DISPOSITION PROCESSED |
| Friday, August 4, 2017 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Friday, June 23, 2017 | CORRECTION UNDER SECTION 7 - PROCESSED |
| Tuesday, June 6, 2017 | ASSIGNED TO PARALEGAL |
| Sunday, May 14, 2017 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Thursday, March 9, 2017 | TEAS SECTION 7 REQUEST RECEIVED |
| Tuesday, February 14, 2017 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, February 1, 2017 | APPLICANT SUPPLIED CHANGES/CORRECTIONS AFTER PUB APPROVAL NOT ENT |
| Tuesday, January 31, 2017 | ASSIGNED TO PETITION STAFF |
| Wednesday, December 28, 2016 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, December 28, 2016 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Friday, December 16, 2016 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Friday, December 16, 2016 | TEAS POST PUBLICATION AMENDMENT RECEIVED |
| Tuesday, November 29, 2016 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, November 29, 2016 | PUBLISHED FOR OPPOSITION |
| Wednesday, November 9, 2016 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, November 9, 2016 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, November 9, 2016 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, October 27, 2016 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Thursday, October 13, 2016 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Saturday, September 24, 2016 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, September 23, 2016 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, September 23, 2016 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Monday, September 19, 2016 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Thursday, September 15, 2016 | ASSIGNED TO LIE |
| Thursday, March 10, 2016 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, March 10, 2016 | LETTER OF SUSPENSION E-MAILED |
| Thursday, March 10, 2016 | SUSPENSION LETTER WRITTEN |
| Tuesday, February 16, 2016 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, February 15, 2016 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, February 15, 2016 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, February 15, 2016 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, February 15, 2016 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, September 4, 2015 | REFUSAL PROCESSED BY IB |
| Friday, August 14, 2015 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, August 14, 2015 | REFUSAL PROCESSED BY MPU |
| Friday, August 14, 2015 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, August 13, 2015 | NON-FINAL ACTION WRITTEN |
| Saturday, August 8, 2015 | ASSIGNED TO EXAMINER |
| Wednesday, July 29, 2015 | APPLICATION FILING RECEIPT MAILED |
| Saturday, July 25, 2015 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, July 23, 2015 | SN ASSIGNED FOR SECT 66A APPL FROM IB |